US Stock MarketDetailed Quotes

KPTI Karyopharm Therapeutics

Watchlist
  • 6.420
  • +0.280+4.56%
Close Mar 21 16:00 ET
  • 6.420
  • 0.0000.00%
Post 16:13 ET
54.03MMarket Cap-0.46P/E (TTM)

Karyopharm Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Karyopharm Therapeutics Q4 2024 Earnings Date

Currency：USDFeb 19, 2025

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
35.67M
30.54M
-5.13M
Miss Est.
+5.71%
-9.50%
-14.39%
EPS
-4.05
-3.60
+0.45
Beat Est.
+25.00%
+33.33%
+11.11%
Analyst Rating
Strong Buy

Mar 22, 2025

Karyopharm Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 38.390M--
--2025/Q1-- / 35.122M--
Feb 19, 20252024/Q430.542M / 35.674M--
Nov 5, 20242024/Q338.783M / 37.924M--
Aug 6, 20242024/Q242.786M / 36.213M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 38.390M--
--2025/Q1-- / 35.122M--
Feb 19, 20252024/Q430.542M / 35.674M--
Nov 5, 20242024/Q338.783M / 37.924M--
Aug 6, 20242024/Q242.786M / 36.213M--

Unlock Free Earnings Estimates

Karyopharm Therapeutics Earnings Reports

  • Karyopharm Therapeutics | 10-K: FY2024 Annual Report

    Feb 19 07:41 ET

  • Karyopharm Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 5, 2024 07:51 ET

  • Karyopharm Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 6, 2024 07:43 ET

  • Karyopharm Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 8, 2024 17:18 ET

    • Read more

    Market Insights
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
    AIPUY
    +14.85%
    New Fortress Energy
    NFE
    +7.92%
    Cars.com
    CARS
    +2.11%
    Halozyme Therapeutics
    HALO
    +1.31%
    Collegium Pharmaceutical
    COLL
    +0.40%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Mar 22, 2025

    Strong Buy

    • Buy

      83.33%

    • Hold

      16.67%

    • Sell

      0.00%

    Price Target

    No Data